Published in Parasitology on July 11, 2006
Molecular Characterization of Echinococcus granulosus from Hydatid Cysts Isolated from Human and Animals in Golestan Province, North of Iran. Iran J Parasitol (2012) 0.89
The EmsB tandemly repeated multilocus microsatellite: a new tool to investigate genetic diversity of Echinococcus granulosus sensu lato. J Clin Microbiol (2009) 0.84
Molecular characterization of Echinococcus granulosus in a hyperendemic European focus, the Republic of Moldova. Parasitol Res (2014) 0.83
Genetic characterization of Echinococcus granulosus from a large number of formalin-fixed, paraffin-embedded tissue samples of human isolates in Iran. Am J Trop Med Hyg (2014) 0.82
Checklist of tapeworms (Platyhelminthes, Cestoda) of vertebrates in Finland. Zookeys (2015) 0.75
Echinococcus ortleppi infections in humans and cattle, France. Emerg Infect Dis (2014) 0.75
Genotype and Phenotype of Echinococcus granulosus Derived from Wild Sheep (Ovis orientalis) in Iran. Korean J Parasitol (2016) 0.75
The complement regulator factor H binds to the surface protein OspE of Borrelia burgdorferi. J Biol Chem (2000) 3.24
Transcriptional regulation of the lactase-phlorizin hydrolase gene by polymorphisms associated with adult-type hypolactasia. Gut (2003) 2.33
Factor H family proteins: on complement, microbes and human diseases. Biochem Soc Trans (2002) 2.23
Complement evasion by Borrelia burgdorferi: serum-resistant strains promote C3b inactivation. Infect Immun (2001) 2.03
The factor H protein family. Immunopharmacology (1999) 1.96
Complement activation after oxidative stress: role of the lectin complement pathway. Am J Pathol (2000) 1.86
Membrane proteins that protect against complement lysis. Springer Semin Immunopathol (1994) 1.83
Each of the three binding sites on complement factor H interacts with a distinct site on C3b. J Biol Chem (2000) 1.82
Localization of the heparin-binding site on complement factor H. J Biol Chem (1991) 1.77
Serum complement and familial combined hyperlipidemia. Atherosclerosis (1997) 1.64
Disseminated toxoplasmosis after liver transplantation: case report and review. Clin Infect Dis (1998) 1.64
Recurrent low back pain and early disc degeneration in the young. Spine (Phila Pa 1976) (1999) 1.59
Nephritogenic lambda light chain dimer: a unique human miniautoantibody against complement factor H. J Immunol (1999) 1.51
The C-terminus of complement regulator Factor H mediates target recognition: evidence for a compact conformation of the native protein. Clin Exp Immunol (2006) 1.50
Liver transplantation in the Nordic countries, 1982-1998: changes of indications and improving results. Scand J Gastroenterol (1999) 1.45
Complement-regulatory proteins in ovarian malignancies. Int J Cancer (1997) 1.44
Functional properties of complement factor H-related proteins FHR-3 and FHR-4: binding to the C3d region of C3b and differential regulation by heparin. FEBS Lett (1999) 1.43
Molecular mechanisms of target recognition in an innate immune system: interactions among factor H, C3b, and target in the alternative pathway of human complement. J Immunol (2000) 1.43
Regulation of complement activation by C-reactive protein: targeting the complement inhibitory activity of factor H by an interaction with short consensus repeat domains 7 and 8-11. J Immunol (1999) 1.42
Immune evasion of tumor cells using membrane-bound complement regulatory proteins. Immunol Today (1999) 1.40
Analysis of the recognition mechanism of the alternative pathway of complement by monoclonal anti-factor H antibodies: evidence for multiple interactions between H and surface bound C3b. FEBS Lett (1996) 1.38
Outbreak of parasitic peritonitis in reindeer in Finland. Vet Rec (2007) 1.37
Molecular genetic characterization of the Fennoscandian cervid strain, a new genotypic group (G10) of Echinococcus granulosus. Parasitology (2003) 1.36
FHL-1/reconectin and factor H: two human complement regulators which are encoded by the same gene are differently expressed and regulated. Mol Immunol (2000) 1.33
Exceptional resistance of human H2 glioblastoma cells to complement-mediated killing by expression and utilization of factor H and factor H-like protein 1. J Immunol (2000) 1.30
Ascitic complement system in ovarian cancer. Br J Cancer (2005) 1.30
The yeast Candida albicans binds complement regulators factor H and FHL-1. Infect Immun (2002) 1.28
Rituximab (anti-CD20) therapy of B-cell lymphomas: direct complement killing is superior to cellular effector mechanisms. Scand J Immunol (2000) 1.28
Complement-resistance mechanisms of bacteria. Microbes Infect (1999) 1.28
The hyphal and yeast forms of Candida albicans bind the complement regulator C4b-binding protein. Infect Immun (2004) 1.25
Time course of complement activation and inhibitor expression after ischemic injury of rat myocardium. Am J Pathol (1994) 1.24
Relapsing fever spirochetes Borrelia recurrentis and B. duttonii acquire complement regulators C4b-binding protein and factor H. Infect Immun (2006) 1.19
A novel phylogeny for the genus Echinococcus, based on nuclear data, challenges relationships based on mitochondrial evidence. Parasitology (2009) 1.19
A phylogeny of members of the family Taeniidae based on the mitochondrial cox1 and nad1 gene data. Parasitology (2008) 1.18
Loss of expression of protectin (CD59) is associated with complement membrane attack complex deposition in myocardial infarction. Lab Invest (1992) 1.16
Muscle blood flow and flow heterogeneity during exercise studied with positron emission tomography in humans. Eur J Appl Physiol (2000) 1.16
Nerve growth factor and brain-derived neurotrophic factor mRNAs are regulated in distinct cell populations of rat heart after ischaemia and reperfusion. J Pathol (2001) 1.15
Conduction block analgesia in the mandible. A comparative investigation of the techniques of Fischer and Gow-Gates. Swed Dent J (1981) 1.15
Expression and function of the complement membrane attack complex inhibitor protectin (CD59) on human breast cancer cells. Lab Invest (1994) 1.15
Successful liver-kidney transplantation in two children with aHUS caused by a mutation in complement factor H. Am J Transplant (2007) 1.12
Resistance of Trichomonas vaginalis to metronidazole: report of the first three cases from Finland and optimization of in vitro susceptibility testing under various oxygen concentrations. J Clin Microbiol (2000) 1.11
The effect of complement factor H Y402H polymorphism on the outcome of photodynamic therapy in age-related macular degeneration. Eur J Ophthalmol (2007) 1.11
Complement activation in the central nervous system following blood-brain barrier damage in man. Ann Neurol (1996) 1.11
Back extensor and psoas muscle cross-sectional area, prior physical training, and trunk muscle strength--a longitudinal study in adolescent girls. Eur J Appl Physiol Occup Physiol (1998) 1.11
Factor H and disease: a complement regulator affects vital body functions. Mol Immunol (1999) 1.09
Lumbar mobility and low back pain during adolescence. A longitudinal three-year follow-up study in athletes and controls. Am J Sports Med (1997) 1.07
[Offer hepatitis B vaccination to the addicts. Transmission of hepatitis B among intravenous drug abusers]. Lakartidningen (1993) 1.07
Different regulation of factor H and FHL-1/reconectin by inflammatory mediators and expression of the two proteins in rheumatoid arthritis (RA). Clin Exp Immunol (2000) 1.07
Microbes bind complement inhibitor factor H via a common site. PLoS Pathog (2013) 1.06
Secretion of soluble complement inhibitors factor H and factor H-like protein (FHL-1) by ovarian tumour cells. Br J Cancer (2002) 1.05
Deficiency of complement defense protein CD59 may contribute to neurodegeneration in Alzheimer's disease. J Neurosci (2000) 1.05
Regulation of complement membrane attack complex formation in myocardial infarction. Am J Pathol (1993) 1.04
Complement activation in circulation and central nervous system after rituximab (anti-CD20) treatment of B-cell lymphoma. Leuk Lymphoma (2001) 1.02
Interactions of soluble CD59 with the terminal complement complexes. CD59 and C9 compete for a nascent epitope on C8. J Immunol (1993) 1.02
Setaria tundra microfilariae in reindeer and other cervids in Finland. Parasitol Res (2008) 1.01
Liver transplantation for familial amyloidotic polyneuropathy (FAP): a single-center experience over 16 years. Am J Transplant (2007) 1.01
Organ-specific autoimmunity and HLA-DR antigens as markers for beta-cell destruction in patients with type II diabetes. Diabetes (1988) 1.00
Complement in acute and chronic arthritides: assessment of C3c, C9, and protectin (CD59) in synovial membrane. Ann Rheum Dis (1996) 1.00
Leisure time physical activity in the young. Correlation with low-back pain, spinal mobility and trunk muscle strength in 15-year-old school children. Int J Sports Med (1993) 1.00
Subject characteristics and low back pain in young athletes and nonathletes. Med Sci Sports Exerc (1992) 0.99
Complement C3b interactions studied with surface plasmon resonance technique. Int Immunopharmacol (2001) 0.99
Susceptibility of human trophoblast to killing by human complement and the role of the complement regulatory proteins. J Immunol (1993) 0.99
The complement-inhibiting protein, protectin (CD59 antigen), is present and functionally active on glomerular epithelial cells. Clin Exp Immunol (1991) 0.98
High-density lipoproteins can act as carriers of glycophosphoinositol lipid-anchored CD59 in human plasma. Immunology (1994) 0.97
Anti-ICAM-1 monoclonal antibody R6.5 (Enlimomab) promotes activation of neutrophils in whole blood. J Immunol (1999) 0.96
Expression of complement membrane regulators membrane cofactor protein (CD46), decay accelerating factor (CD55), and protectin (CD59) in human malignant gliomas. Am J Pathol (1996) 0.96
Expression and function of the complement membrane attack complex inhibitor protectin (CD59) in human prostate cancer. Int J Cancer (1997) 0.94
Complement C4 deficiency and HLA homozygosity in patients with frequent intraoral herpes simplex virus type 1 infections. Clin Infect Dis (2001) 0.93
Shedding and enrichment of the glycolipid-anchored complement lysis inhibitor protectin (CD59) into milk fat globules. Immunology (1995) 0.93
Complement activation by circulating serum factors in human glomerulonephritis. Clin Exp Immunol (1985) 0.93
Complement-mediated killing of microtumors in vitro. Am J Pathol (1998) 0.93
Urinary excretion of protectin (CD59), complement SC5b-9 and cytokines in membranous glomerulonephritis. Kidney Int (1995) 0.93
Targeted neutralization of the complement membrane attack complex inhibitor CD59 on the surface of human melanoma cells. Eur J Immunol (1994) 0.93
Complement-regulator factor H and related proteins in otitis media with effusion. Clin Immunol (2001) 0.92
Acquired resistance of Escherichia coli to complement lysis by binding of glycophosphoinositol-anchored protectin (CD59). Infect Immun (1998) 0.92
Complement activation and regulator expression after anoxic injury of human endothelial cells. APMIS (1998) 0.91
Complement C3 cleavage and cytokines interleukin-1beta and tumor necrosis factor-alpha in otitis media with effusion. Laryngoscope (2000) 0.91
The morphology of the filaroid nematode Setaria tundra, the cause of peritonitis in reindeer Rangifer tarandus. J Helminthol (2007) 0.91
Decreased expression of protectin (CD59) in gut epithelium in ulcerative colitis and Crohn's disease. Hum Pathol (1999) 0.91
Co-deposition of clusterin with the complement membrane attack complex in myocardial infarction. Immunology (1993) 0.90
Testicular lesions of streptozotocin diabetic rats. Horm Res (1975) 0.90
Outcome following liver transplantation for primary sclerosing cholangitis in the Nordic countries. Scand J Gastroenterol (2003) 0.89
Induced expression of neuronal membrane attack complex and cell death by Alzheimer's beta-amyloid peptide. Brain Res (1998) 0.89
Protection of gingival epithelium against complement-mediated damage by strong expression of the membrane attack complex inhibitor protectin (CD59). J Dent Res (1996) 0.89
Urinary excretion of cytokines and complement SC5b-9 in idiopathic membranous glomerulonephritis. Nephrol Dial Transplant (1994) 0.89
High pentraxin-3 plasma levels associate with thrombocytopenia in acute Puumala hantavirus-induced nephropathia epidemica. Eur J Clin Microbiol Infect Dis (2011) 0.88
Survival of Helicobacter pylori From complement lysis by binding of GPI-anchored protectin (CD59). Gastroenterology (2001) 0.88
Release of endogenous anti-inflammatory complement regulators FHL-1 and factor H protects synovial fibroblasts during rheumatoid arthritis. Clin Exp Immunol (2003) 0.88
An immunofluorescence assay for complement activation by the classical pathway. J Immunol Methods (1981) 0.88
Treating missing data in a clinical neuropsychological dataset--data imputation. Clin Neuropsychol (2001) 0.88
Upregulation of major histocompatibility complex class II antigens in hepatocytes in Doberman hepatitis. Vet Immunol Immunopathol (2003) 0.87
Haemangiosarcoma in dogs. J Comp Pathol (1978) 0.87
Parapoxvirus infection in Norwegian semi-domesticated reindeer (Rangifer tarandus tarandus). Vet Rec (2001) 0.87
Cytolytic complement activity in otitis media with effusion. Clin Exp Immunol (2001) 0.86
Complement activation and expression of membrane regulators in the middle ear mucosa in otitis media with effusion. Clin Exp Immunol (1999) 0.86